First indication of human safety and PK profiles for SPR720 supports advancement of program to a Phase 2a proof-of-concept clinical trial in patients planned to initiate in the second half of 2020 CAMBRIDGE, MA, USA I December 04, 2019 I Spero Therapeutics, Inc....
–Study Achieves All Primary Endpoints; Company to Set Meeting with FDA Regarding Pivotal Trial Design– PHILADELPHIA, Dec. 4, 2019 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating...
–Clinical Trial Aims to Confirm Data Showing that Cognizance’s EvoScoreDX Protein Biomarker Assay Can Accurately Distinguish Epileptic Seizures from Psychogenic Seizures– SPRING HOUSE, Pa., Dec. 4, 2019 /PRNewswire/ — Cognizance Biomarkers,...
Top-line results expected in the second half of 2020 Ra Pharmaceuticals, Inc. (RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). “IMNM is a chronic, severe, and...
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligo Top-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, CA, USA I December 03, 2019 I Dermavant Sciences, a dermatology-focused subsidiary of Roivant...
SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ — Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study with its lead nanocatalytic therapy, CNM-Au8, for the treatment...
Email
Text